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delivery for severe PE at less than 34  weeks gestation. 
However, there was no relevant evidence for women with 
severe PE over 34 weeks.
Conclusions In women with PE or gestational hyper-
tension beyond 34  weeks gestation, elective delivery can 
decrease the incidence of complications, severe hyperten-
sion and the need for antihypertensive drug therapy. Elec-
tive delivery can also lower the risk of placental abrup-
tion in women before 34 weeks gestation with severe PE, 
however, may be associated with increased risk of neonatal 
complications.
Keywords Pre-eclampsia · Expectant management · 
Deliver · Obstetric · Meta-analysis
Introduction
Pre-eclampsia (PE) is a pregnancy-specific condition char-
acterized by hypertension and consequent damage to other 
organs (e.g. kidney, liver) [1]. PE occurs in approximately 
2–8 % of pregnancies, typically in the second or third tri-
mester, and is considered as one of the most common, 
dangerous, and unpredictable complications of pregnancy 
[1–3]. Women with PE are at an approximately fourfold 
higher risk of death than those without PE. Additionally, 
babies born to mothers with PE have substantially increased 
odds of death and severe complications [4]. Common risk 
factors for PE are listed in Table 1 [3, 5]. While the exact 
mechanisms underlying PE remain unclear, some evidence 
suggests that it may be related to inadequate blood supply 
to the placenta and the resultant hypoxic environment [6]. 
Infants born after PE are at increased risk of “small for ges-
tational age”, and severe and early onset PE were associ-
ated with significant fetal growth restriction [7].
Abstract 
Purpose To evaluate the effectiveness and safety of elec-
tive delivery versus expectant management for women with 
pre-eclampsia (PE) and to assess neonatal outcomes before 
and after 34 weeks gestation.
Methods We searched Biomed Central, CINAHL, 
Cochrane Library, Embase, HMIC, Medline, and WHO 
trial registry, British Nursing Index, ClinicalTrials.gov, 
Current Controlled Trials, and Web of Science on 16 
March, 2016. 1704 citations were identified. Randomised 
controlled trials comparing elective delivery with expect-
ant management for women with PE were included. Seven 
studies were included (n = 1501). There were no maternal 
deaths.
Results Elective delivery lowered incidence of compli-
cations in women with PE or hypertension greater than 
34 weeks gestation (n = 756; RR, 0.64; 95% CI 0.51–0.80). 
For women with severe PE less than 34  weeks gestation, 
elective delivery lowered the incidence of placental abrup-
tion (n = 483, 5 RCTs; RR, 0.43; 95% CI 0.19–0.98). For 
women with PE or hypertension greater than 34  weeks 
gestation, elective delivery also reduced the need for anti-
hypertensive drug therapy. The need for ventilatory sup-
port and the risk of developing neonatal intraventricular 
hemorrhage or hypoxic ischemic encephalopathy may 
be increased in infants whose mothers undergo elective 
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According to published clinical guidelines, the man-
agement of PE is primarily dependent on two important 
factors: the gestational age and the severity of the disease 
[8–10]. Because delivery is the only curative treatment for 
PE, the timing of delivery is critical for clinical outcomes. 
The American College of Obstericians and Gynecologists 
(ACOG) taskforce bulletin indicates delivery at 37 weeks of 
gestation for women with PE (including gestational hyper-
tension) [10]. Although preterm delivery may be consid-
ered for women with severe PE, clinicians should carefully 
evaluate the serious consequences and adverse outcomes 
associated with PE progression over the risks of preterm 
birth. There is controversy regarding the benefits of elec-
tive delivery over expectant management before 34 weeks 
of gestation for women with PE. The National Institute for 
Health and Clinical Excellence (NICE) guidelines generally 
recommend not to perform elective delivery for PE man-
agement before 34 weeks of gestation unless severe refrac-
tory hypertension or above-threshold (pre-documented in a 
consultant plan) maternal or fetal indications develop after 
a course of corticosteroids treatment [9]; while the ACOG 
taskforce bulletin states that “continued pregnancy should 
be undertaken only at facilities with adequate maternal and 
neonatal intensive care resources for women with severe 
PE at less than 34  weeks of gestation” without providing 
further instructions as to whether elective delivery can be 
performed if certain conditions occur [10]. Despite these 
guideline recommendations, many clinicians still consider 
that active PE intervention after 34 weeks of gestation pro-
motes a better outcome for both the mother and neonate. 
However, evidence supporting these management crite-
ria is very limited. A recently published Cochrane review 
compared the effects of a policy of interventionist care 
and early delivery (before 34  weeks of gestation) with a 
policy of expectant care and delayed delivery for women 
with early onset severe PE, but women with non-severe PE 
were not included in the analysis [11]. In addition, although 
the Cochrane review reported that expectant management 
may be associated with decreased infant mortality before 
34 weeks of gestation, it was unable to reach a conclusion 
regarding maternal outcomes because of insufficient data, 
therefore, more evidence will be required to provide guid-
ance regarding management of PE, in general, and severe 
PE before 34 weeks’ gestation [11].
The objectives of this meta-analysis were to compare (1) 
the maternal and fetal outcomes of elective delivery versus 
expectant management; (2) the optimal timing of deliv-
ery (before 34 weeks of gestation versus after 34 weeks of 
gestation) for preventing PE-associated complications. We 
classified the patient population as having “PE in general” 
and “severe PE” and performed separate analyses for each 
patient group.
Materials and methods
Sources. The following databases were searched from their 
establishment dates to 29 June, 2014: Biomed Central; 
British Nursing Index; CINAHL; Cochrane Library; Clini-
calTrials.gov; Current Controlled Trials; Embase; HMIC; 
Medline; Web of Science; and the WHO trial registry. 
After the trial search, the review protocol was registered 
on PROSPERO International Prospective Register of Sys-
tematic Review. The registration code is CRD42013004741 
[12]. We updated the search at 16 March, 2016.
Study selection The severity of PE is determined by 
both clinical features and the presence of certain labora-
tory abnormalities. We adopted the diagnostic criteria for 
PE and severe PE stated in American College of Obstetri-
cians and Gynecologists (ACOG) guideline. The diagnostic 
criteria were presented it in Table 2 [13, 14]. Severe PE is 
associated with major adverse outcomes, such as seizures, 
hemorrhagic and ischemic strokes, placental abruption and 
stillbirth. “HELLP syndrome” is a variant of severe pre-
eclampsia that is characterized by hemolysis, elevated liver 
enzymes, and low platelets. Hepatic failure, liver rupture, 
renal dysfunction or irreversible renal failure secondary 
to renal cortical necrosis has also been reported [15]. As 
defined in ACOG guideline, the gestational hypertension is 
‘BP elevation after 20 weeks of gestation in the absence of 
proteinuria or the aforementioned systemic findings [13].
We included studies if they were (1) randomised con-
trolled trials, (2) evaluated any methods of elective delivery 
(induction of labour or caesarean section) versus expectant 
management (policy of delayed delivery), and (3)included 
treatment of women with pre-eclampsia (however defined) 
Table 1  Common risk factors for pre-eclampsia
Pregnancy-specific issues
Nulliparity












 Connective tissue disorder (e.g. systemic lupus erythematosus)
 Family history or pre-eclampsia
Lack of smoking
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or gestational hypertension, who either before or at-term 
delivery (up to and greater than 34  weeks). Cluster-ran-
domised studies and studies with a quasi-random design, 
such as allocation by alternation, day of week, or hospi-
tal numbers were excluded, as they have a greater poten-
tial for bias [16]. Studies with a crossover design were 
also excluded, since such a design is not possible with this 
intervention.
Outcomes. Our primary maternal outcomes included 
(1) death, (2) eclampsia, and (3) stroke, and (4) any seri-
ous morbidity or complications (defined as at least one 
complication of stroke, placental abruption, kidney failure, 
liver failure, HELLP syndrome, disseminated intravascu-
lar coagulation, pulmonary edema and postpartum hem-
orrhage). Maternal secondary outcomes included: severe 
hypertension and need for hypertensive drug therapy. Pri-
mary neonatal outcomes included (1) stillbirth, (2) perina-
tal death, and (3) neonatal death. Secondary neonatal out-
comes included: necrotizing enterocolitis, requirement for 
ventilatory support, cerebral hemorrhage, interventricular 
hemorrhage or hypoxic ischemic encephalopathy, hyaline 
membrane disease, bronchopulmonary dysplasia and pneu-
mothorax and small-for-gestational age.
Data extraction and management. Review authors YW 
and Min Hao (MH) independently extracted data relating 
to our outcomes of interest into an electronic proforma. We 
sub-categorized results into groups according to gestational 
age at trial entry: less than or greater than 34  weeks of 
pregnancy. We carried out the statistical analysis using the 
Review Manager v5.3 software, using a fixed-effect model 
for meta-analysis combining data where trials examined the 
same intervention, and the trials’ populations and methods 
were judged sufficiently similar. For binary/dichotomous 
outcomes, we obtained estimates of the treatment effect 
using the risk ratio (RR) and its 95% confidence interval 
(CI). For continuous outcomes, we used a mean difference 
(MD). Where we suspected clinical or methodological het-
erogeneity between studies, sufficient to suggest that treat-
ment effects may differ between trials, we used a random 
effects model. We investigated heterogeneity between stud-
ies by considering the I2 method alongside the chi-square p 
value.
Assessment of risk of bias. The Cochrane Handbook 
for Systemic Reviews of Interventions was considered 
when assessing risk of bias in the included studies [17]. 
Methodological quality was rated as either a ‘low’, ‘high’ 
or ‘unclear’ risk of bias based on domains, including ran-
domization, allocation concealment, blinding, incomplete 
outcome data and selective reporting.
Assessment of the quality of evidence. The GRADE 
methodology was applied for evaluating the quality of evi-
dence for the primary maternal outcomes that the authors 
had consistently identified as important. We judged the 




The first phrase search yielded 1529 references after dupli-
cates were removed and the updated search yielded 175 ref-
erences of which seven studies were included in the final 
report (Fig.  1). The seven studies fulfilling our inclusion 
criteria were (HYPITAT-I 2009, Mesbah 2003, MEXPRE 
Table 2  Diagnostic criteria for pre-eclampsia and severe pre-eclampsia [13, 14]
Name Diagnostic criteria
Pre-eclampsia Hypertension (a blood pressure greater than or equal to 140 mmHg systolic or equal to 90 mmHg 
diastolic on two occasions at least 4 h apart after 20 weeks of gestation in a women with a previously 
normal blood pressure) or severe hypertension (systolic blood pressure ≥160 mmHg or diastolic blood 
pressure ≥110 mmHg on two occasions 4 h apart)
And
Proteinuria (‘≧300 mg per 24-h urine collection’ or ‘Protein/creatinine ratio ≧0.3 mg/dL’ ‘Dipstick read-
ing of 1+, used only if other quantitative methods not available’)
Or
In the absence of proteinuria, new-onset hypertension with the new onset of any of the following: throm-
bocytopenia, impaired liver function, the new development of renal insufficiency, pulmonary edema or 
new onset cerebral or visual disturbance
Severe pre-eclampsia Severe hypertension alone: systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥110 mmHg
Or severe hypertension with the following criteria
Severe proteinuria at least 3 g (range 2–5 g) protein in 24 h, or 3+ on dipstick
Oliguria <500 cc/day upper abdominal pain, pulmonary oedema
Neurological disturbances (such as headache, visual disturbances, and exaggerated tendon reflexes)
Impaired liver function tests, high serum creatinine, low platelets
Suspected intrauterine growth restriction or reduced liquor volume
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2013, Odendaal 1990, Sibai 1994, Duvekot 2015 and a sub-
set of participants from the GRIT study [18–27]). A total 
of 1,501 participants were included (range 30–756), 481 
were diagnosed with severe PE, 264 with pre-eclampsia 
and severe hypertensive disorders, and 756 with PE and 
gestational hypertension (Table  3). One identified studies 
is on-going trial [28]. Therefore, six studies provided data 
[21–25, 27].
Study characteristics
In the six studies that provided data for women with severe 
PE who were preterm delivery, definitions of the disorder 
were comparable between studies. Maternal and gestational 
ages as well as the length of pregnancies were also fairly 
uniform (Table 3) [21–24, 27]. One study provided data for 
women with PE who were pre- and post-term, and gesta-
tional hypertension between 36 and 41 weeks [18–20, 26]. 
Procedures for elective delivery in the intervention groups 
with severe pre-eclampsia were comparable among the 
five studies, with delivery required within 24–72  h after 
the admission or after administration of steroids. Elective 
delivery was either via induction of labour or caesarean 
section (CS). The choice to induce labour or perform a CS 
was based on obstetrical indications, such as malpresenta-
tion, hypertensive disorders, and dystocia [21–24]. In one 
study of women with pre-eclampsia, labour was induced 
within 24 h following randomization [18–20, 26].
Fig. 1  PRISMA flow diagram. After screening of duplicates and eligibility, seven studies were included in our analysis
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Maternal death and eclampsia
There were no maternal deaths or strokes in any of the 
included studies in women with severe PE, PE or gesta-
tional hypertension (n = 1020). Three studies reported the 
incidence of eclampsia; only one study reported one case of 
eclampsia in each group of MEXPRE 2013 in women less 
than 34 weeks gestation with severe PE [21], however, the 
difference was not significant (n = 389, 3 RCTs, RR 1.02, 
95 CI 0.06–16.06, p = 0.99).
Maternal complications
In pregnant women with PE greater than 34 weeks gesta-
tion, elective delivery significantly lowered the incidence of 
any maternal complication (n = 756, 1 RCT; RR, 0.64; 95% 
CI 0.51–0.80, p = 0.0001; Fig.  2). Though elective deliv-
ery was also associated with a lower incidence of HELLP 
syndrome in women with PE or gestational hypertension 
greater than 34 weeks gestation (1.06 vs 2.9%), the differ-
ence was not significant (n = 756, 1 RCT; RR,0.37; 95% CI 
0.12–1.14, p = 0.08).
In women with severe PE less than 34  weeks gesta-
tion, elective delivery was associated with a significantly 
lower incidence of placental abruption (n = 483, 5 RCTs; 
RR, 0.43; 95% CI 0.19–0.98, p = 0.04; Fig. 3). There was 
no significant difference in the incidence of renal failure 
(n = 427, 4 RCTs; RR, 0.33; 95% CI 0.05–2.03, p = 0.23) 
or HELLP syndrome (n = 389, 3 RCTs; RR, 1.12; 95% 
CI 0.64–1.97, p = 0.69) between the management groups. 
There was no incidence of disseminated coagulopathy in 
the elective delivery group. Two patients in the expectant 
management group experienced this complication, how-
ever, this difference was not significant (n = 359, 2 RCTs; 
RR, 0.20; 95% CI 0.01–4.17, p = 0.30).
There were no significant differences between the 
management groups in the incidence of pulmonary edema 
in women with severe PE less than 34  weeks gestation 
(n = 415, 3 RCTs; RR, 0.46; 95% CI 0.07–3.05, p = 0.42) 
or PE / hypertension greater than 34  weeks gestation 
(n = 756, 1 RCT; RR, 0.20; 95% CI 0.01–4.17, p = 0.30). 
The incidence of postpartum hemorrhage (>500 ml blood 
loss) was also similar between the groups in women 
with PE or hypertension greater than 34 weeks (n = 756, 
1RCT; RR, 0.88; 95% CI 0.57–1.35, p = 0.56).
Fig. 2  Elective delivery versus expectant management, maternal outcome: PE related complications. PE related complications were decreased 
in puerperas that elective delivery compared to in puerperas that expectant management (RR < 1)
Fig. 3  Elective delivery versus expectant management, maternal outcome: placental abruption. Occurrence of placental abruption in puerperas 
that elective delivery was lower than in puerperas that expectant management (RR < 1)
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Maternal hypertension
Women with PE or gestational hypertension greater than 
34 weeks who underwent elective delivery experienced less 
of an increase in both diastolic (n = 756, 1 RCT; RR, 0.61; 
95% CI 0.46–0.80, p = 0.0005) and systolic blood pressure 
(n = 756, 1 RCT; RR, 0.63; 95% CI 0.46–0.85, p = 0.003). 
There was also a significant difference between the man-
agement groups in terms of a requirement for antihyperten-
sive drug therapy. Significantly fewer women greater than 
34  weeks gestation with PE or hypertension who under-
went elective delivery required either oral or intravenous 
antihypertensive drug therapy (n = 756, 1 RCT; RR, 0.61; 
95% CI 0.46–0.79, p = 0.0003) and (n = 756, 1 RCT; RR, 
0.34; 95% CI 0.18–0.62, p = 0.0005), respectively. This was 
also the case for women less than 34 weeks gestation with 
severe PE (n = 264, 1 RCT; RR, 0.01; 95% CI 0.00–0.13, 
p = 0.0006).
Fetal and neonatal mortality
The pooled analysis indicated that there was no any differ-
ence in the incidence of fetal or neonatal mortality between 
the management groups in women less than 34 weeks ges-
tation with severe pre-eclampsia (n = 689, 5 RCTs; RR, 
0.30; 95% CI 0.07–1.22, p = 0.09) and (n = 485, 5 RCTs; 
RR, 1.34; 95% CI 0.82–2.20, p = 0.24), respectively. There 
were no neonatal or fetal deaths reported in women greater 
34  weeks’ gestation with PE or gestational hypertension 
(n = 756, 1 RCT).
Neonatal complications
Overall estimates showed that there was no difference 
between the management groups in the incidence of neo-
natal necrotising enterocolitis in women less than 34 weeks 
gestation with severe PE (n = 659, 4 RCTs; RR, 1.78; 
95% CI 0.83–3.79, p = 0.14). However, neonates whose 
mother’s underwent elective delivery for severe PE at less 
than 34 weeks gestation required more ventilatory support 
than neonates whose mother’s in this group were managed 
expectantly (n = 300, 2 RCTs; RR, 1.50; 95% CI 1.11–2.02, 
p = 0.009; Fig.  4). There was no significant difference in 
the incidence of cerebral hemorrhage (n = 95, 1 RCT; RR, 
3.20; 95% CI 0.34–29.63, p = 0.31) between the manage-
ment groups in neonates of mother’s less than 34  weeks 
gestation with severe PE.
Neonates whose mother’s underwent an elective deliv-
ery at less than 34 weeks for severe PE had a higher inci-
dence of interventricular hemorrhage or hypoxic ischemic 
encephalopathy compared to neonates whose mothers in 
this group were managed expectantly (n = 526, 2 RCTs; 
RR, 1.94; 95% CI 1.15–3.28, p = 0.01; Fig. 5).
In neonates whose mothers were admitted with severe 
PE less than 34 weeks gestation, the incidence of hyaline 
membrane disease was similar in both management groups 
(n = 397, 3 RCTs, RR 1.66, 95% CI 0.92–2.99, p = 0.09). 
There was also no significant difference between the man-
agement groups in the incidence of bronchopulmonary 
dysplasia (n = 95, 1 RCT; RR, 2.13; 95% CI 0.41–11.08, 
p = 0.37) or pneumothorax (n = 40, 1 RCT; RR, 3.00; 95% 
CI 0.34–26.45, p = 0.32) in this group of women. Sig-
nificantly more neonates whose mothers were managed 
expectantly with severe PE at less than 34 weeks gestation 
were small-for-gestational age (SGA) (n = 389, 3 RCTs; 
RR, 0.37; 95% CI 0.23–0.60, p < 0.0001).
Risk of bias assessment
Six out of the seven studies adequately described the 
method of randomization, and two studies were rated as a 
‘high’ risk of bias across one or more of the pre-specified 
domains examining methodological quality (Fig.  6 pro-
vides a graphical overview of the risk of bias rating within 
each included study). One study expressly mentioned an 
‘open-label’ design with regards to blinding participants 
[18–20, 26], however, all of the remaining studies failed to 
mention the blinding methods used. Due to the nature of 
Fig. 4  Elective delivery versus expectant management, neonatal outcome: ventilated. Occurrence of ventilated in neonates that undergo elective 
delivery was higher than in neonates that undergo expectant management (RR > 1)
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the intervention, it is clear that any level of double blind-
ing is not possible or indeed ethical. However, one study 
did mention that an attempt was made to blind the treat-
ment allocator to the data abstracter and neonatologist [22]. 
One study selectively excluded women with a more severe 
level of PE, after elective delivery via CS [21]. Risk of bias 
assessment was not possible with all included studies due 
to a lack of methodological detail in the studies’ design. 
These are all factors that may increase the risk of bias in 
included studies and affect the quality of the evidence.
Quality assessment of the evidence
We have summarized the quality of evidence for the pri-
mary maternal outcomes in Table 4.
Discussion
This meta-analysis evaluated the effectiveness of elective 
delivery versus expectant management performed either 
before or after 34 weeks of gestation in women with PE in 
general or severe PE. Below we summarize our findings by 
patient outcomes. With respect to maternal outcomes, the 
incidence of eclampsia was similar for elective delivery 
and expectant management across all patient groups. The 
evidence for this finding is graded as moderate. For the 
prevention of maternal complications (e.g. placental abrup-
tion, HELLP syndrome), moderate evidence has suggested 
that elective delivery significantly reduced the incidence of 
all maternal complications compared with expectant man-
agement after 34 weeks of gestation in women with PE in 
general; high quality evidence has suggested that elective 
delivery also significantly decreased the incidence of pla-
cental abruption before 34  weeks of gestation in women 
with severe PE. No significant differences between the 
two interventions were found in preventing other mater-
nal complications (renal failure, HELLP syndrome, dis-
seminated coagulopathy, pulmonary edema and postpartum 
hemorrhage) regardless of gestation age or PE severity. 
This result was supported by moderate or low quality evi-
dence. Regarding the management of hypertension, elec-
tive delivery was associated with significantly less increase 
Fig. 5  Elective delivery versus expectant management, neonatal out-
come: interventricular hemorrhage or hypoxic ischemic encephalopa-
thy. Interventricular hemorrhage or hypoxic ischemic encephalopathy 
in neonates that undergo elective delivery was higher than in neonates 
that undergo expectant management (RR > 1)
Fig. 6  Risk of bias assessment: provides a graphical overview of the 
risk of bias rating within each included study
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in diastolic and systolic blood pressure and lower rates of 
antihypertensive drug therapy than expectant delivery after 
34 weeks of gestation in women with PE; elective delivery 
was also associated with significantly fewer patients requir-
ing antihypertensive drug therapy before 34 weeks of ges-
tation in women with severe PE. These results were sup-
ported by moderate evidence.
With respect to neonatal outcomes, evidence was only 
available for before 34 weeks of gestation in women with 
severe PE. No difference existed between elective delivery 
and expectant management in fetal and neonatal mortal-
ity. For the prevention of neonatal complications, elective 
delivery resulted in significantly higher rate of ventilation 
use and interventricular hemorrhage/hypoxic ischemic 
encephalopathy than expectant management before 
34  weeks of gestation in women with severe PE. How-
ever, expectant management was associated with a sig-
nificantly increased incidence of small neonates for their 
gestation age compared with elective delivery in the same 
patient population. No significant differences between the 
two interventions were found in preventing other neonatal 
complications, including necrotizing enterocolitis, cerebral 
hemorrhage, hyaline membrane disease, bronchopulmo-
nary dysplasia, or pneumothorax before 34 weeks of gesta-
tion in women with severe PE.
One Cochrane review, published in 2013, com-
pared the outcomes of elective delivery versus expect-
ant management in women with severe PE between 24 
and 34 weeks’ gestation [14]. This review included four 
small trials with a total of 425 patients. Because of the 
small sample size, the evidence was insufficient to per-
mit reliable conclusions on maternal outcomes. Regard-
ing neonatal outcomes, the Cochrane review reported that 
in women with severe PE between 24 and 34  weeks of 
gestation, elective delivery was associated with increased 
neonatal morbidity relative to expectant management. 
In comparison to the Cochrane review, this analysis 
included two additional recent, large RCTs (n = 756, and 
n = 264) in the addition of 1020 patients [18, 22]. This 
allows us to assess both maternal and neonatal outcomes. 
Our assessment of neonatal outcomes indicated that elec-
tive delivery resulted in a higher rate of neonatal com-
plications than expectant management before 34  weeks’ 
gestation in women with severe PE, which is consistent 
with the Cochrane review. However, our analysis also 
revealed that elective delivery may decrease the incidence 
of placental abruption in the same patient population. In 
light of the dilemma in maternal and neonatal outcomes, 
clinicians should carefully balance the risks versus ben-
efits of elective delivery in women with severe PE before 
34-weeks’ gestation to achieve optimal outcomes for both 
the mother and baby. Given that the risk of placental 
abruption may outweigh that of neonatal complications, 
elective delivery could be more beneficial than expectant 
management to high risk women with severe PE before 
34 weeks’ gestation.
An additional strength of our review is that we used the 
GRADE system to rate the quality of the evidence base. 
When providing guidance for clinical decision making, a 
recommendation should inform the clinicians of not only 
the benefits and risks associated with a particular interven-
tion but also the reliability of that recommendation. Failure 
to consider the quality of the evidence base on which the 
recommendation is derived may lead to misguidance [29]. 
Our rating of the evidence base using the GRADE system 
has provided the clinicians with a concise summary of 
the quality of the evidence without including unnecessary 
details.
Some changes were made to the protocol of this review 
after registration [11]. To improve clarity and distinguish 
this review from the existing Cochrane review, we changed 
the title from ‘interventionist versus expectant management 
for pre-eclampsia’ to ‘elective delivery versus expectant 
management for pre-eclampsia.
The limitations of this analysis should be mentioned. 
In our search strategy, we specifically searched for stud-
ies including participants with a diagnosis of PE. There-
fore, we may have overlooked some studies that included 
an unspecified subset of women with PE. Another limita-
tion is that our general PE group included patients with 
gestational hypertension. Unlike the Cochrane review, our 
analysis intended to compare elective delivery and expect-
ant management in women with PE, in general, in addition 
to women with severe PE. One large RCT in our search 
results, the HYPITAT-I trial allowed for this comparison 
[18]. However, the enrollment criterion for the HYPITAT-I 
trial was gestational hypertension or mild PE. Because this 
trial did not report separate outcomes for the two condi-
tions, it is impossible to tease out the outcomes for PE only. 
Also, the women included in this study had a gestation age 
between 36 and 41  weeks, which was slightly above the 
median gestational age in other studies that contributed 
data to the patient group above 34 weeks? Gestation [18]. 
Given the consideration that studies including women with 
non-severe PE are sparse, and that this study has directly 
informed national and international guidelines on recom-
mendations for PE management, we decided to include this 
study in our analysis despite its mixed patient population 
(PE and gestational hypertension). Including the HYPI-
TAT-I trial offered the benefit of adding 756 patients; this 
large sample size permitted a conclusion in women with PE 
in general. Moderate evidence demonstrated that elective 
delivery may prevent maternal complications in women 
with PE beyond 34 weeks of pregnancy. However, it should 
be noted that the general PE group in our analysis included 
patients with gestational hypertension.
621Arch Gynecol Obstet (2017) 295:607–622 
1 3
We are unable to report the outcomes in women with 
severe PE beyond 34 weeks of gestation because of the lack 
of evidence, although these outcomes are within the initial 
scope of this analysis. The absence of evidence partially 
ascribes to the termination of pregnancy typically per-
formed in this patient population. As termination of preg-
nancy is recommended in women with severe PE beyond 
34  weeks of gestation by the Federation of Gynecology 
and Obstetrics, expectant management is rarely used in this 
population. Since evidence suggests that elective delivery 
is generally more beneficial than expectant management in 
women with severe PE below 34 weeks of gestation, it is 
reasonable to speculate that elective delivery should also 
be recommended in severe PE patients beyond 34  weeks 
of gestation. In summary, our analysis provides insights 
into the effectiveness of elective delivery versus expectant 
management, as well as the timing of the interventions in 
managing PE, in general, and severe PE. However, future 
studies will be required to verify the results of our analy-
sis. The studies that can provide strong evidence should be 
RCTs with a large sample size, adequate randomization, 
and outcome assessors blinded to the treatments. Although 
our analysis included studies of non-severe PE, the num-
ber of these studies is low. We identified only one appropri-
ate study of non-severe PE in women before 34 weeks of 
gestation and one in women beyond that gestation age, and 
both studies included women with gestational hypertension 
[18, 27]. Therefore, a convincing conclusion on PE, in gen-
eral, requires more RCTs conducted in a homogenous PE 
patient population (preclude gestational hypertension) but 
including patients with severe and non-severe PE. Regard-
ing outcomes, more RCTs will be required to report on 
any maternal complications, increase in blood pressure 
and postpartum hemorrhage, particularly, in patients with 
severe PE.
Conclusion
Elective delivery is generally more beneficial than expect-
ant management for women with PE or gestational hyper-
tension beyond 34  weeks of gestation and women with 
severe PE. This intervention can reduce the risk of PE-
related complications and lower the incidence of severe 
hypertension and the need for antihypertensive medication 
in women with PE beyond 34  weeks of gestation; it can 
also reduce the risk of placental abruption in women with 
severe PE before 34  weeks of gestation. However, elec-
tive delivery may increase the rate of ventilation use and 
the risk of interventricular hemorrhage/hypoxic ischemic 
encephalopathy in neonates. More data from RCTs with 
larger sample sizes will be required to further evaluate the 
benefits and harm of elective delivery versus expectant 
management for women and neonatal outcomes.
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